Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
2,433,848
-
Share change
-
+754,516
-
Total reported value
-
$9,479,585
-
Price per share
-
$3.90
-
Number of holders
-
34
-
Value change
-
+$3,269,998
-
Number of buys
-
18
-
Number of sells
-
5
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q2 2018
As of 30 Jun 2018,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,433,848 shares.
The largest 10 holders included
SABBY MANAGEMENT, LLC, VANGUARD GROUP INC, JPMORGAN CHASE & CO, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., Psagot Investment House Ltd., MORGAN STANLEY, NORTHERN TRUST CORP, and ETF MANAGERS GROUP, LLC.
This page lists
34
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.